Acyclovir_COA_13711_MedChemExpress
降胆固醇药物的新作用
降胆固醇药物的新作用
麦田
【期刊名称】《心血管病防治知识》
【年(卷),期】2009(0)3
【摘要】@@ 早在2008年初,就提出一个医学难题:为什么降低胆固醇药物,不能减少动脉的粥样斑块?
【总页数】1页(P53)
【作者】麦田
【作者单位】(Missing)
【正文语种】中文
【相关文献】
1.一种新的降胆固醇药物 [J], 曾凡贤
2.FDA批准了降胆固醇药物ZETIA的新适应证 [J],
3.降胆固醇药物的新作用浅析 [J], 吴振宇
4.我国科学家揭示胆固醇吸收的分子机制及降胆固醇药物“益适纯”的作用原理[J],
5.HMG—CoA还原酶抑制剂——一种新的降胆固醇药物 [J], 田浩明;梁荩忠因版权原因，仅展示原文概要，查看原文内容请购买。
CAS号413611-93-5_10074-G5_MedBio_物理性质
1、产品物理参数：
常用名
10074-G5
英文名
10074-G5
CAS号
413611-93-5
分子量
332.313
密度
1.4±0.1 g/cm3
沸点
538.6±60.0 °C at 760 mmHg
分子式
C18H12N4O3
熔点
无资料
闪点
279.5±32.9 °C
2、技术资料：
体外研究
10074-G5抑制Daudi Burkitt淋巴瘤细胞的生长并破坏c-Myc / Max二聚化。针对Daudi和HL-60细胞的IC50值分别为15.6和13.5μM[1]。10074-G5在区域Arg363-Ile381中结合Myc肽Myc353-437，Kd值为2.8μM。10074-G5结合在由诱导螺旋结构域（Leu370-Arg378）的N末端的扭结（Asp379-Ile381）产生的空腔中[3]。
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11457
CDK inhibitor II
CDK inhibitor II
1269815-17-9
50mg
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11591
(S)-CCG-1423
(S)-CCG-1423
None
体内研究
静脉注射20 mg / kg小鼠的血浆半衰期为10074-G5，为37分钟，血药浓度峰值为58μM，比肿瘤峰值浓度高10倍[1]。
3、同类产品列表：
ICU患者万古霉素血药浓度监测及其临床应用
•临床药学・ICU患者万古霉素血药浓度监测及其临床应用方芳-李宁2,徐春丽杨继红1*，郑志昌Z（1.贵州医科大学附属医院药剂科，贵州贵阳550001；2.中国药科大学，药学国家实验教学示范中心，江苏南京211198）摘要：目的超高效液相测定ICU患者血清中万古霉素，探讨其峰、谷浓度与疗效、安全性的关系。
方法血清用10%高氯酸沉淀，梯度洗脱，流动相为乙腈：0.005mol-L-1磷酸二氢钾缓冲液。
结果万古霉素不受內源性物质干扰，线性良好，准确度、回收率、精密度、稳定性均符合要求。
峰、谷浓度分别为15.42〜89.12、7.30〜55.46 mg-L-1，谷浓度与肾毒性有弱相关性（相关系数r=0.3772，P<0.05），谷浓度超过24mg-L-1易发生肾毒性。
结论该方法快速、高效，适用于临床血药浓度监测。
关键词：万古霉素；超高效液相色谱法;峰谷浓度;肝肾毒性中图分类号:R969文献标识码:A文章编号：2095-5375（2021）04-0272-006doi：10.13506/ki.jpr.2021.04.015Determination of serum vancomycin in ICU patients and its clinical applicationF^NG Fang1,U Ning2Chunli1,Y4NG丿ihong1*,ZHENG Zhichang1*(/.Department of Pharmaceutics,4^liated Hospital of Guizhou Medical University, Guiyang550001,China;2.National Experimental Teaching Demonstration Center of Pharmacy,China Pharmaceutical University, Nan/ing211198,China)Abstract:Objective To develop a rapid ultra-performance liquid chromatographic(UHPLC)method for determination of vancomycin in serum from ICU patients,and investigate the relationship between serum peak-to-valley concentrations of vancomycin and its efficacy and safety.Methods Serum samples were precipitated with10%perchloric-acid,and subsequently analyzed via gradient elution.The mobile phase consisted of acetonitrile and0.005mol-L-1KH2PO4 buffer.Results The chromatographic peaks of vancomycin was not interfered by endogenous matrixes.The linearity of vancomycin was satisfactory.The precision,recovery rate,precision and stability of vancomycin all met the requirement of biological samples analysis.In ICU patients, the vancomycin serum peak and trough concentration were15.42-89.12mg-L-1 and7.30~55.46mg-L-1,respectively.Spearman correlation analysis showed that there was a weak correlation between serum valley concentration and nephrotoxicity(correlation coefficient r=0.3772,P<0.05).Nephrotoxicity readily occurred when the serum valley concentration exceeded24mg•L-1.Conclusion The rapid UHPLC method with high efficiency was suitable for the therapeutic drug monitoring(TDM)of vancomycin.Key words:Vancomycin;Ultra-performance liquid chromatographic(UHPLC);Serum peak-to-valley concentrations; Liver and kidney toxicity近年来，随着革兰阳性菌多重耐药的问题日益突出。
非奈利酮在2_型糖尿病合并慢性肾病治疗中的应用进展
非奈利酮在2型糖尿病合并慢性肾病治疗中的应用进展赵东坤淄博市中心医院药品调剂科，山东淄博255036[摘要]2型糖尿病合并慢性肾病（diabetic nephropathy, DN）患病率高、危害性大，以慢性白蛋白尿和肾小球滤过障碍为主。
非奈利酮是目前临床上最常用的一种醛固酮受体阻断药，也是临床上最常用的一种药物，另外常用药还有：依普利酮、螺内酯等。
本次研究主要针对非奈利酮在2型糖尿病合并慢性肾病治疗中的应用进展进行分析。
[关键词] 非奈利酮；2型糖尿病；慢性肾病；治疗[中图分类号] R4 [文献标识码] A [文章编号] 1672-4062（2023）09（b）-0187-04 Application of Finelidone in the Treatment of Type 2 Diabetes Mellitus Complicated with Chronic Kidney DiseaseZHAO DongkunDepartment of Drug Dispensing, Zibo Central Hospital, Zibo, Shandong Province, 255036 China[Abstract] Type 2 diabetes mellitus complicated with chronic nephropathy (DN) is a dangerous disease with high prevalence, mainly chronic albuminuria and glomerular filtration disorders. Fenelidone is currently the most com‐monly used aldosterone receptor blocker in clinical practice, and is also the most commonly used drug in clinical prac‐tice. In addition, commonly used drugs include epinephrine, spironolactone. In this study, the application of finelidone in the treatment of type 2 diabetes mellitus combined with chronic kidney disease was analyzed.[Key words] Finelidone; Type 2 diabetes; Chronic kidney disease; Heal糖尿病肾病的出现，主要是由于长期高血糖所致的肾脏二次损害，糖尿病肾病的进展速度较快，出现终末期的危险性较高，所以要注意延缓肾功能的恶化。
Calcipotriol_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Sep.-13-2017Print Date:Sep.-13-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :CalcipotriolCatalog No. :HY-10001CAS No. :112965-21-61.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:MC 903; CalcipotrieneFormula:C27H40O3Molecular Weight:412.60CAS No. :112965-21-64. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature: 4°C, protect from light, stored under nitrogenShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
760-78-1_DL-正缬氨酸_MED11074技术资料_上海_Medbio脉铂
1g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11127
Fmoc-L-丝氨酸
Fmoc-Ser-OH
73724-45-5
100g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
CAS
包装
纯度
MedBio
MED11025
N-羟基琥珀酰亚胺
HOSu
6066-82-6
100g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11040
丝氨酸苄酯盐酸盐
H-Ser-OBzl.HCl
1738-72-3
100g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11086
5g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11059
N-Fmoc-N'-Boc-L-2,3-二氨基丙酸
Fmoc-Dap(Boc)-OH
162558-25-0
1g
≥98%
纯度
MedBio
MED11049
Fmoc-N-三苯甲基-L-天冬酰胺
Fmoc-Asn(Trt)-OH
132388-59-1
100g
≥98%
品牌
货号
中文名称
子学习情境5
子学习情境5氢化可的松发酵任务一甾类药物甾类药物是指分子结构中含有环戊烷多氢菲核的一类药物，在医学上应用非常广泛，特 别是甾体激素类药物，应用在风湿性关节炎，控制炎症，避孕，利尿等各方面的治疗上，对 机体起着非常重要的调节作用。
甾类激素根据其生理活性可分为肾上腺皮质激素，性激素和 蛋白同化激素三大类。
、肾上腺皮质激素皮质激素两大类。
糖皮质激素如可的松(cortiso ne )和氢化可的松(hydrocortisone )是由肾上腺束状带细胞所合成和分 泌，主要影响人体的糖、蛋白质和脂肪的代谢，对水、盐的 代谢作用影响较小。
临床上主要用于抗炎、抗毒素、抗休克 和抗过敏等。
以醛甾酮和去氧皮甾酮为代表的盐皮质激素是由肾上腺的球状带细胞分泌，主 要作用是促进钠离子肾小管的重吸收，从而使钠的排泄量减小，促进钾的排泄。
临床上主要 用于治疗慢性肾上腺皮质机能减退症(阿狄森病)及低血钠症。
、性激素性激素的重要生理功能是刺激副性器官的发育和成熟，激发副性特征的出现，增进两性 生殖细胞的结合和孕育能力，还有调节代谢的作用。
按其生理功能可分为雄性激素和雌性激 素两类。
雄性激素属于C 19类固醇，主要由睾丸和肾上腺皮质所产生，卵巢也有少量合成。
睾丸 分泌的雄激素主要有3种：睾酮、脱氢异雄酮和雄烯二酮。
雌性激素包括雌激素和孕激素两类，主要由卵巢合成和分泌，肾上腺皮质和睾丸也能少 量合成。
雌激素，真正由腺体分泌，有活性的只有 3种：17P -雌二醇、雌酮和雌三醇。
三种 激素生理活性相差很大，其相对比活为100 : 10 : 3。
孕激素属于C 21类固醇，体内真正存在的 是孕酮。
三、蛋白同化激素蛋白同化激素是一类从睾丸酮衍生物中分化出来的药物， 特点是性激素的作用大为减弱, 蛋白质同化作用仍然保留甚至增强，临床使用比较安全，较少引起男性化症状等不良反应。
如17a-甲基去氢睾丸素(17-methyldehydro-testosterone 商品名为大力补)。
Keap1
非小细胞肺癌(non-small cell lung cancer，NSCLC)发病率占据肺癌的75%~80%。
肿瘤细胞进展快且易扩散转移，临床常采用手术、放化疗等进行治疗，但5年生存率低于60%[1-2]。
氧化应激是由活性氧(ROS)生成量增加所致，ROS积累可诱导肺癌细胞凋亡，清除ROS 可阻止癌细胞凋亡，即肺癌细胞存活依赖于癌细胞自身抗氧化能力[3]。
Kelch样环氧氯丙烷相关蛋白-1 (kelch-like epichlorohydrin-associated protein-1，Keap1)/核因子E2相关因子2(nuclear factor E2related factor 2，Nrf2)信号通路在癌症中发挥重要调控作用，氧化应激可激活Keap1，促使Keap1-Nrf2复合物裂解，Nrf2转移至细胞核内，可激活下游靶基因表达，参与肺癌发生发展过程[4]。
Nrf2可维持氧化还原稳态，ROS侵袭细胞时，Nrf2可进入细胞核，结合抗氧化反应元件(ARE)转录编码各种抗氧化蛋白、代谢酶基因，抑制氧化应激反应[5-6]。
目前氧化应激、Keap1/Nrf2信号通路在NSCLC发生过程中的机制尚未明确。
基于此，本研究尝试分析Keap1/Nrf2信号通路与临床病理参数、氧化应激指标的相关性，探讨其在NSCLC氧化应激机制中的作用，为临床研制新药提供参考依据。
1资料与方法1.1一般资料选取2017年4月至2020年4月郑州市第三人民医院收治的100例NSCLC患者为研究对象。
纳入标准：符合NSCLC诊断标准[7]；术前未接受放化疗、免疫治疗者；预计生存期≥6个月；符合手术适应证、禁忌证；Karnofsky功能状态评分≥70分；签署知情同意书。
排除标准：合并凝血功能障碍、肝肾功能障碍、其他恶性肿瘤者；伴有急/慢性感染者；伴有精神疾病者；既往腹部相关外科手术史者。
所有患者均行肺癌根治性切除术，术中收集癌组织、癌旁组织(距离癌组织5cm范围内正常组织)，其中男性63例，女性37例；年龄46~67岁，平均(56.32±3.16)岁；体质量指数(BMI)17~30kg/m2，平均(23.16±2.03)kg/m2；病理类型：鳞癌58例、腺癌42例；病理分级[8]：Ⅰ~Ⅱ级51例、Ⅲ级49例；T分期[9]：T1~T253例、T3~T447例；N分期：N055例、N1~N245例。
伐昔洛韦联合甲钴胺治疗带状疱疹的临床效果
- 23 -①丰城市第三人民医院药剂科 江西 丰城 331100通信作者：段翔伐昔洛韦联合甲钴胺治疗带状疱疹的临床效果段翔①【摘要】 目的：探究伐昔洛韦与甲钴胺联合应用治疗带状疱疹的临床效果。
方法：选取2020年1月—2022年1月于丰城市第三人民医院进行治疗的102例带状疱疹患者作为研究对象，采用信封法将其分为参考组与研究组，患者均接受常规治疗，其中参考组的51例患者在常规治疗基础上服用甲钴胺，研究组的51例患者则在上述基础上应用伐昔洛韦。
对比两组的治疗总有效率及康复时间；对比两组患者治疗前后的疼痛情况、睡眠质量及炎症指标水平[中性粒细胞（NEU）、淋巴细胞（LYM）与超敏C 反应蛋白（hs-CRP）]。
结果：研究组治疗总有效率（96.08%）高于参考组（82.35%），差异有统计学意义（χ2=4.993，P <0.05）。
研究组的皮损愈合、疱疹干燥结痂及局部疼痛消失时间均早于参考组，差异均有统计学意义（P <0.05）。
治疗后，研究组的数字分级评分法（NRS）、匹兹堡睡眠质量指数（PSQI）评分均低于参考组，且NEU、LYM 与hs-CRP 水平均低于参考组，差异均有统计学意义（P <0.05）。
结论：带状疱疹患者予以伐昔洛韦联合甲钴胺治疗，效果较为理想，该治疗方案能促进患者的临床症状消失，缓解疼痛，改善睡眠质量，还能降低其炎症水平。
【关键词】 带状疱疹 伐昔洛韦 甲钴胺 Clinical Effect of Valacyclovir Combined with Mecobalamin in the Treatment of Herpes Zoster/DUAN Xiang. //Medical Innovation of China, 2024, 21(04): 023-027 [Abstract] Objective: To investigate the clinical effect of Valaciclovir combined with Mecobalamine in the treatment of herpes zoster. Method: A total of 102 patients with herpes zoster treated in the Third People's Hospital of Fengcheng City from January 2020 to January 2022 were selected as research objects. They were divided into reference group and study group by envelope method. All patients received conventional treatment, and 51 patients in the reference group received Mecobalamine in addition to conventional treatment. The 51 patients in the study group received Valaciclovir on the above basis. The total effective rate and recovery time of the two groups 囊切除术的镇痛效果观察[J].黑龙江医药，2022，35（6）：1269-1273.[14]陈俊霖.腹直肌鞘联合腹横肌平面阻滞在小儿腹腔镜下阑尾切除术中应用价值的分析[D].延吉：延边大学，2022：20-26.[15]田迪，邱永升，贾英萍.纳布啡超前镇痛联合超声引导下腹直肌鞘阻滞应用于单孔腹腔镜小儿疝手术的效果[J].河南外科学杂志，2022，28（6）：18-20.[16] LIANG M，XV X，REN C，et al.Effect of ultrasound-guidedtransversus abdominis plane block with rectus sheath block on patients undergoing laparoscopy-assisted radical resection of rectal cancer: a randomized, double-blind, placebo-controlled trial[J].BMC Anesthesiol，2021，21（1）：89.[17]付品国.术前和术后超声引导下腹直肌鞘阻滞在妇科单孔腹腔镜手术患者术后镇痛的比较[D].温州：温州医科大学，2022：19-20.[18]江家美，邹振民，吕纯，等.超声引导下腹横筋膜平面阻滞在妇科单孔腹腔镜术后镇痛中的应用[J].中国医学创新，2022，19（34）：23-27.[19]范祥春，李利，罗婉飞，等.超声引导腹直肌后鞘阻滞在经脐单孔腹腔镜手术患者中加速康复的临床观察[J].中国医药科学，2021，11（5）：177-181.[20]张鹤晨，张静，蔚冬冬，等.罗哌卡因复合布托啡诺腹横肌平面阻滞对妇科腹腔镜手术患者术后镇痛及早期康复的影响[J].临床麻醉学杂志，2020，36（2）：156-159.[21]彭俊，沈翔，黄勇，等.超声引导下腹横肌平面阻滞对子宫肌瘤腹腔镜手术患者Ramsay 评分及加速康复外科的影响[J].中国妇幼保健，2020，35（15）：2913-2916.（收稿日期：2023-06-09） （本文编辑：白雅茹） 水痘-带状疱疹病毒是一种将人类作为唯一宿主的病毒，由该病毒病毒感染所致的带状疱疹则是临床常见传染性急性皮肤病。
心肌灌注显像半定量分析对不同缺血程度老年冠状动脉粥样硬化性心脏病的诊断价值
2021年 2月第 42 卷$ 第 1 期Feb. 2021Vol. 42 No. 1首都医科大学学报Journal of Capital Medical University[doi : 10. 3969/j. issn 1006-7795. 2021. 01. 005 ]・核医学基础与临床*基金项目：北京市医院管理局"登峰"计划专项经费资助(DFL 20180802) $ This study was supported by Beping Municipal Administration of Hospitals" Ascent Plan ( DFL 20180802).* Corresponding author , E-mail : imaginglu@ hotmail. com网络出版时间：2021 -01 -19 13： 03 网络出版地址：https ：//k*s. okU net/kcms/detaii/11.3662. R. 20210119. 1000.010. html心肌灌注显像半定量分析对不同缺血程度老年冠状动脉粥样硬化性心脏病的诊断价值谷珊珊1!2卢 洁1>3'4* 陈 冈『(1.首都医科大学宣武医院核医学科，北京100053； 2.民航总医院核医学科，北京100123； 3.首都医科大学宣武医院放射科,北京100053； 4.磁共振成像脑信息学北京市重点实验室，北京100053)【摘要】目的 探讨核素心肌灌注显像(myocardial petusion imaging, MPI)半定量分析不同缺血程度对老年冠状动脉粥样硬化性心脏病(coonao arteo disease , CAD ,以下简称冠心病)的诊断价值。
方法 以2017年8月至2020年6月于民航总医院行两 日法静息-负荷心肌灌注显像的99例患者为研究对象,所有患者均于6个月内行冠状动脉造影(coonao angmgophy , CAG )，根据CAG 结果分为冠心病组52例(病例组)和非冠心病组47例(对照组)。
多靶点酪氨酸激酶抑制剂阿西替尼治疗肝纤维化的作用与机制
ll
i
ve
rc
e
l
ll
i
ne (
LO2 )we
r
ei
n
t
e
r
venedwi
t
hd
i
f
f
e
r
en
tconc
en
t
r
a
t
i
on
s
o
fAx
i
t
i
n
i
b
-CMCs
o
l
u
t
i
on.MTTa
s
s
aywa
spe
r
f
o
rmed48hand72ha
f
t
e
rt
hei
n
t
e
r
ven
t
i
on.F
l
owcy
t
ome
t
r
CCL4 诱导的 小 鼠 肝 组 织 纤 维 增 生 的 影 响 以 及 对 体
外 HSC 系(
LX2)细 胞 活 性 及 细 胞 凋 亡 的 影 响,探 究
2mL/kg 的橄 榄 油,每 周 2 次,连 续 4 周;
CCl4 造 模
2 周组、
4 周 组,用 CCl4 橄 榄 油 溶 液 分 别 造 模 处 理
肝组织,以 100mL/L 甲醛固定,制作石蜡切片,进行
后续分析。
1.
3 肝组织切片染色 对各组切片进行 HE 染色与
Ma
s
s
on 染色,显微镜下观 察。光镜下,胶原纤维被染
成蓝绿色,每样本随机选取 15 个高倍视野(